Literature DB >> 7660803

[Relationship between the molecular composition of C1027, a new macromolecular antibiotic with enediyne chromophore, and its antitumor activity].

R G Shao1, Y S Zhen.   

Abstract

The molecule of C1027, an antitumor antibiotic with extremely potent cytotoxicity against cultured cancer cells, is composed of an enediyne chromophore and an apoprotein of 10.5 kDa. These two parts of the molecule, connecting each other through non-covalent binding, can be dissociated and reconstituted. As determined by clonogenic assay, the chromophore served as the active part of the molecule, displaying potent cytotoxicity similar to that of intact C1027. The activity of free chromophore decreased more rapidly than that of intact C1027, indicating that apoprotein played a role in protecting the chromophore from inactivation. By incubating together in phosphate buffer, the chromophore and apoprotein were reconstituted to form an intact C1027. The ratio of chromophore and apoprotein remained 1 : 1 in the reconstituted molecule, even though extra amount of chromophore was added. The optimal condition for the reconstitution was pH 7.0, at 20 degrees C for 12 h. When the disulfide bond of the apoprotein was reduced by DTT, the activity of C1027 decreased more rapidly. C1027 was digested by pronase and the produced fragments of various molecular weights were examined by capillary electrophoresis. The cytotoxicity of 3-5 kDa fragment approximated that of intact C1027 and its IC50 value was 0.07 fmol.L-1. The results indicate that the intactness of the apoprotein is not indispensable for stabilizing the chromophore and a smaller molecule of 3-5 kDa consisting of a peptide fragment and a chromophore may retain full C1027 activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7660803

Source DB:  PubMed          Journal:  Yao Xue Xue Bao        ISSN: 0513-4870


  10 in total

1.  Mitotic cell death in BEL-7402 cells induced by enediyne antibiotic lidamycin is associated with centrosome overduplication.

Authors:  Yue-Xin Liang; Wei Zhang; Dian-Dong Li; Hui-Tu Liu; Ping Gao; Yi-Na Sun; Rong-Guang Shao
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

2.  Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule.

Authors:  Yun-Hong Huang; Bo-Yang Shang; Yong-Su Zhen
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

3.  Pharmacokinetics of C-1027 in mice as determined by TCA-RA method.

Authors:  You-Ping Liu; Quan-Sheng Li; Yu-Rong Huang; Mao-Jin Zhou; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

4.  Tissue distribution and excretion of 125I-lidamycin in mice and rats.

Authors:  You-Ping Liu; Quan-Sheng Li; Yu-Rong Huang; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

5.  Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma.

Authors:  Liang Li; Yun-Hong Huang; Yi Li; Feng-Qiang Wang; Bo-Yang Shang; Yong-Su Zhen
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

6.  Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice.

Authors:  Yong-Zhan Zhen; Ya-Jun Lin; Yi Li; Yong-Su Zhen
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

7.  Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase.

Authors:  Yong-Zhan Zhen; Ya-Jun Lin; Bo-Yang Shang; Yong-Su Zhen
Journal:  Int J Hematol       Date:  2009-05-26       Impact factor: 2.490

8.  A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.

Authors:  Shiming He; Chunyan Zhao; Hongyu Tao; Weijin Sheng; Ruijuan Gao; Xiujun Liu; Yongsu Zhen
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

9.  An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.

Authors:  Jian Xu; Xiu-Jun Liu; Liang Li; Sheng-Hua Zhang; Yi Li; Rui-Juan Gao; Yong-Su Zhen
Journal:  Oncotarget       Date:  2015-09-22

10.  Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy.

Authors:  Gen-Shen Zhong; Min-Na Wu; Xiao-Fang Guo; Zhi-Shan Xu; Sheng-Hua Zhang; Yong-Su Zhen
Journal:  Oncol Lett       Date:  2013-01-18       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.